Vlad Coric, Biohaven CEO
November 10, 2022 11:15 AM ESTUpdated March 22, 10:05 AM
Financing

Bio­haven claims $300M+ pub­lic of­fer­ing as com­pa­ny charts new jour­ney af­ter Pfiz­er buy­out

Paul Schloesser

Associate Editor

Bio­haven re­port­ed its Q3 earn­ings Wednes­day, just a few weeks af­ter Pfiz­er made a ma­jor pur­chase of the com­pa­ny’s CGRP port­fo­lio. And tucked away in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times